Muscle Fatigue and Carbonic Anhydrase Inhibitors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this research is to assess the effects of acetazolamide and methazolamide on respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for the respiratory and plantar flexor muscles and the difference in pressure/torque produced by supramaximal nerve stimulation used to assess muscle fatigue between conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of EPA and HMB on Strength in ICU Patients

NCT01270516

Muscle Weakness

COMPLETED NA

Study of Muscle Repair Following Exercise in Young and Elderly People

NCT02174692

Healthy

COMPLETED NA

Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients

NCT03469271

Cancer

COMPLETED PHASE4

Kinematical and Muscular Fatigue in Swimmers

NCT06069440

Healthy

COMPLETED NA

Muscle Reflex Inhibition in Hypoxic Exercise

NCT05619887

Dyspnea Muscle Strain

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypoxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acetazolamide

Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.

Group Type EXPERIMENTAL

Acetazolamide

Intervention Type DRUG

250 mg, taken orally three times per day

Methazolamide

Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.

Group Type EXPERIMENTAL

Methazolamide

Intervention Type DRUG

100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.

Placebo

Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

A placebo will be taken three times per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acetazolamide

250 mg, taken orally three times per day

Intervention Type DRUG

Methazolamide

100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.

Intervention Type DRUG

Placebo

A placebo will be taken three times per day

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-40 years.
* Regularly physically active
* Male

Exclusion Criteria

* current or ex-smokers
* pulmonary function \<80% of predicted
* esophageal tumour or ulcer
* have had recent (\<6 months) musculoskeletal injury or any surgery to the lower leg
* have contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis)
* are obese (BMI \>30 Kg/m2)
* taking diuretics, blood thinners, or anti-platelet drugs.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes